<DOC>
	<DOCNO>NCT00048165</DOCNO>
	<brief_summary>The purpose study compare number randomized participant treatment group experience acute rejection episode first 6 month undergoing cardiac transplantation .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Zenapax Combination With CellCept , Cyclosporine , Corticosteroids Patients Undergoing Cardiac Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Participants must undergo first cardiac allograft transplant Women childbearing potential must negative serum pregnancy test within 48 hour prior transplantation Women childbearing potential must use two reliable form contraception simultaneously . Effective contraception must use begin study drug therapy , 4 month follow discontinuation study drug therapy Participants and/or guardian must willing capable understanding risk comply purpose study Previous organ transplant Participants receive multiple organ Participants require ventricular assist device ( VAD ) upon completion transplantation surgery Women lactating , pregnant childbearing potential use , unwilling use two reliable form contraception simultaneously study History psychological illness condition would interfere participant 's ability understand requirement study White blood count = &lt; 2500/mm^3 , platelet = &lt; 50,000/mm^3 hemoglobin = &lt; 6 g/dL HIV1 , presence positive HBsAg , chronic active hepatitis C Active peptic ulcer disease Severe diarrhea gastrointestinal disorder might interfere ability absorb oral medication Malignancies within past 5 year , exclude skin carcinoma adequately treat Participants receive within past 30 day require concomitant treatment investigational drug immunosuppressive medication prohibit study Inability start microemulsion form cyclosporine within 72 hour</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>